SE0000307D0 - Method and formulation för treatment of vasoconstriction - Google Patents

Method and formulation för treatment of vasoconstriction

Info

Publication number
SE0000307D0
SE0000307D0 SE0000307A SE0000307A SE0000307D0 SE 0000307 D0 SE0000307 D0 SE 0000307D0 SE 0000307 A SE0000307 A SE 0000307A SE 0000307 A SE0000307 A SE 0000307A SE 0000307 D0 SE0000307 D0 SE 0000307D0
Authority
SE
Sweden
Prior art keywords
vasoconstriction
formulation
treatment
compositions
precursors
Prior art date
Application number
SE0000307A
Other languages
English (en)
Inventor
Ralph A Schmid
Gabriele Schoedon
Original Assignee
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Zuerich filed Critical Univ Zuerich
Priority to SE0000307A priority Critical patent/SE0000307D0/sv
Publication of SE0000307D0 publication Critical patent/SE0000307D0/sv
Priority to AU2001226609A priority patent/AU2001226609A1/en
Priority to PCT/CH2001/000062 priority patent/WO2001056551A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE0000307A 2000-01-31 2000-01-31 Method and formulation för treatment of vasoconstriction SE0000307D0 (sv)

Priority Applications (3)

Application Number Priority Date Filing Date Title
SE0000307A SE0000307D0 (sv) 2000-01-31 2000-01-31 Method and formulation för treatment of vasoconstriction
AU2001226609A AU2001226609A1 (en) 2000-01-31 2001-01-26 Method and formulation for treatment of vasoconstriction
PCT/CH2001/000062 WO2001056551A2 (en) 2000-01-31 2001-01-26 Method and formulation for treatment of vasoconstriction

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0000307A SE0000307D0 (sv) 2000-01-31 2000-01-31 Method and formulation för treatment of vasoconstriction

Publications (1)

Publication Number Publication Date
SE0000307D0 true SE0000307D0 (sv) 2000-01-31

Family

ID=20278294

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0000307A SE0000307D0 (sv) 2000-01-31 2000-01-31 Method and formulation för treatment of vasoconstriction

Country Status (3)

Country Link
AU (1) AU2001226609A1 (sv)
SE (1) SE0000307D0 (sv)
WO (1) WO2001056551A2 (sv)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005018620A2 (en) * 2003-08-26 2005-03-03 Cell Center Cologne Gmbh Use of nitric oxide synthase (nos) cofactor for the treatment of sexual dysfunction
KR20060120147A (ko) * 2003-10-31 2006-11-24 알타나 파마 아게 호흡 질환의 치료를 위한 ｂｈ4의 용도
DK1708690T3 (en) 2003-11-17 2016-11-07 Biomarin Pharm Inc TREATMENT OF PHENYLKETONURI WITH BH4
JP2008540486A (ja) * 2005-05-11 2008-11-20 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｄｅ４インヒビター及びテトラヒドロビオプテリン誘導体との組合せ物
EP1965803A1 (en) * 2005-12-05 2008-09-10 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of disease
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
CN109640957A (zh) * 2016-06-13 2019-04-16 梅哈里医学院 一氧化氮合酶途径对口腔健康的调节

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552267A (en) * 1992-04-03 1996-09-03 The Trustees Of Columbia University In The City Of New York Solution for prolonged organ preservation

Also Published As

Publication number Publication date
WO2001056551A3 (en) 2002-07-11
AU2001226609A1 (en) 2001-08-14
WO2001056551A2 (en) 2001-08-09

Similar Documents

Publication Publication Date Title
MY143795A (en) Tetrahydropyridoindole derivatives
CO5700767A2 (es) Procedimiento de tratamiento de rechazo de transplantes
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
DE60112609D1 (en) Pyrazolopyridine
YU23102A (sh) Jedinjenja za lečenje ishemije
DK1299348T3 (da) Forbindelser og sammensætninger til levering af aktive midler
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
YU46200A (sh) N-(supstituisani peto-članog di-ili triaza dinezasićenog prstena)karbonil/guanidin derivati za tretiranje ishemije
HK1079519A1 (en) Furyl compounds
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
ECSP045004A (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes
DE69713151D1 (de) Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung
DK1052905T3 (da) Kimhæmmende fremgangsmåde til rodknolde og lög med anvendelse af eugenol og/eller isoeugenol
EA200600280A1 (ru) Композиции на основе производных липопептидных антибиотиков и способы их применения
TR200200883T2 (tr) 2-ikameli 1,1-bifenil-2-karbonamidler, imalat yöntemleri, ilaç olarak kullanılmaları
ATE300541T1 (de) Pyrazolopyridinderivate
YU87202A (sh) Derivati arilmetilamina koji se koriste kao inhibitori triptaze
MY128061A (en) A pharmaceutical formulation comprising a low molecular weight thrombin inhibitor and its prodrug
WO2002043706A3 (en) Prolamin-based sustained-release compositions and delayed-onset compositions
SE0000307D0 (sv) Method and formulation för treatment of vasoconstriction
RS50148B (sr) Upotreba docetaksela za lečenje hepatoćelijskog karcinoma
ATE324112T1 (de) Topische behandlung bei der mastalgie
DK1307445T3 (da) Benzofuranderivater og deres anvendelse som antibakterielle midler
TR200402070T4 (tr) Siklobüten-dion türevleri ve bunların damar sertliği tedavisinde kullanımı
RS20060154A (en) Anti-tumor formulations comprising defibrotide alone or in combination with other anti-tumor agents